HER2-targeting antigen binding constructs and uses thereof
By introducing specific amino acid mutations into the scFv antigen binding fragment of HER2 targeted antibodies, the problem of antibody aggregation is solved, its binding affinity for HER2 and its anti-tumor effect is improved, and the toxicity is reduced, and a stable antibody construct design is achieved.
Patent Information
- Application Number
- CN202410892747.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-30
- Filing Date
- 2021-04-29
- Publication Date
- 2024-11-12
AI Technical Summary
There are aggregation problems in existing HER2 antibody drugs in industrial applications, resulting in difficulties in expression, purification, immunogenicity, toxicity and storage activity, and the single-chain molecule scFv is prone to aggregate to form dimers, trimers and tetramers. The aggregate affects its stability and effect.
An antigen binding construct is designed that contains a scFv antigen binding fragment of the ECD4 antigen monovalently binding to HER2 ECD4 antigen, by introducing specific amino acid mutations in the heavy and light chain variable regions, such as position 30 of the Kabat numbering system The K or E mutation at position 53 reduces the aggregation of the antibody and improves its affinity and stability by binding to the specific sequence and ligation of the fragment.
It has achieved the reduction of antibody aggregation, maintained or improved binding affinity for HER2 antigen, significantly improved the anti-tumor performance and safety of antibodies, such as the killing and proliferation inhibitory effect on tumor cells with multiple HER2 expression levels, while reducing toxicity. effect.
Smart Images

Figure CN118924894A_ABST
Abstract
Description
[0001] This application is a divisional application. The filing date of the original application is April 29, 2021, the application number is 202180020300.4, and the name of the invention is “Antigen-binding constructs targeting HER2 and their uses”. Technical Field
[0002] The present invention relates to an antigen-binding construct, and in particular to an antigen-binding construct targeting HER2 and uses thereof. Background Art
[0003] Her2 (human epidermal growth factor receptor 2), also known as ErbB-2 (Receptor tyrosine-protein kinase erbB-2), is a member of the human epidermal growth factor receptor (HER / EGFR / ERBB) family, which includes EGFR (ErbB-1), Her2 / c-neu (ErbB-2), Her3 (ErbB-3) and Her4 (ErbB-4). The Her2 protein has an extracellular ligand binding domain (domain I-IV), a transmembrane domain and an intracellular domain. The ligand of Her2 is unknown. Her2 forms heterodimers with any of the other three receptors (ErbB-1, ErbB-3, ErbB-4). Dimerization leads to autophosphorylation of tyrosine residues in the cytoplasmic domain of the receptor and activates multiple signaling pathways, including MAPK (mitogen-activated protein kinase), PI3K / Akt (phosphoinositide 3-kinase), PKC (protein kinase C), and STAT (Signal transducer and activator of transcription). The amplification or overexpression of the Her2 gene plays an important role in the occurrence and development of certain invasive breast cancers. 15% to 30% of breast cancer patients are Her2 positive. Her2 is an important biomarker and therapeutic target for breast cancer patients. In addition, 7% to 34% of gastric cancer patients overexpress Her2, and 30% of salivary duct carcinomas overexpress Her2.
[0004] Several Her2-targeted antibody drugs for the treatment of Her2-positive tumors have been launched, including Roche's monoclonal antibody targeting Her2 extracellular domain IV (ECD4). Roche's Her2 extracellular domain II (ECD2) And Roche ADC drugs (ado-trastuzumab memtansine). The mechanisms of action of these monoclonal antibody drugs include: 1) downregulation of Her2 signaling, 2) binding to Her2 epitopes to form signaling heterodimers, 3) endocytosis of Her2, and 4) antibody-dependent cellular cytotoxicity (ADCC). Monospecific targeting does not target other target epitopes that may be involved in signaling and pathogenesis, allowing for drug resistance and escape mechanisms.
[0005] The aggregation of antibodies will bring difficulties in expression and / or purification, immunogenicity, toxicity, degradation, impaired affinity, or loss of activity after storage. Therefore, in industrial applications, it is necessary to reduce the aggregation of antibodies. For scFv, it is a single-chain molecule, which is more prone to aggregation and can aggregate to form dimers (diabodies), trimers (triabodies) and tetramers (tetrabodies). Summary of the invention
[0006] The present invention provides an antigen-binding construct, which reduces the aggregation of the antigen-binding construct. The present invention also provides the use of the antigen-binding construct.
[0007] On the one hand, the present invention provides an antigen-binding construct, comprising a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, preferably, the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, preferably, the mutated amino acid is Y.
[0008] Alternatively, the present invention provides an antigen-binding construct comprising a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid at position 30 according to the Kabat numbering system that is K or E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid at position 53 according to the Kabat numbering system that is F or Y; however, when the amino acid at position 30 according to the Kabat numbering system of the heavy chain variable region of the first antigen-binding fragment is K, the amino acid at position 53 according to the Kabat numbering system of the light chain variable region of the first antigen-binding fragment is not F.
[0009] In some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system, or / and the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system. In some specific embodiments, the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system. In other specific embodiments, the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system. In some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system, and the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system.
[0010] In some embodiments, the first antigen-binding fragment comprises a group of CDRs selected from:
[0011] i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively;
[0012] ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively;
[0013] iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0014] iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0015] v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0016] vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0017] vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively;
[0018] viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively; or
[0019] ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
[0020] The sequence shown in SEQ ID NO: 27 is GNFIX2DTYIH, and X2 is K or E; the sequence shown in SEQ ID NO: 34 is SASX1LYS, and X1 is F or Y.
[0021] In some embodiments, the first antigen-binding fragment comprises a heavy chain variable region of trastuzumab or a mutant thereof, and a light chain variable region of trastuzumab or a mutant thereof, wherein the mutant of the heavy chain variable region comprises a K30E mutation according to the Kabat numbering system, and the mutant of the light chain variable region comprises a F53Y mutation according to the Kabat numbering system.
[0022] In some embodiments, the first antigen-binding fragment is selected from:
[0023] i. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 41 and 42, respectively;
[0024] ii. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 41 and 42, respectively;
[0025] iii. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 35 and 36, respectively;
[0026] iv. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 35 and 39, respectively; or
[0027] v. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 40 and 36, respectively;
[0028] Among them, the sequence shown in SEQ ID NO: 41 is:
[0029] EVQLVESGGGLVQPGGSLRLSCAASGFNIX2DTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS, X2 is K or E;
[0030] The sequence shown in SEQ ID NO: 42 is:
[0031] DIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASX1LYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK, X1 is F or Y.
[0032] In some embodiments, the antigen-binding construct described herein further comprises a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells. In some embodiments, the second antigen-binding fragment is a Fab. In some embodiments, the second antigen-binding fragment comprises the heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, and light chain CDR3 of Pertuzumab. In some embodiments, the second antigen-binding fragment comprises the heavy chain variable region of Pertuzumab and the light chain variable region of Pertuzumab.
[0033] In one aspect, the invention provides a pharmaceutical composition comprising an antigen binding construct according to the present invention and a pharmaceutically acceptable carrier.
[0034] In one aspect, the invention provides an isolated nucleic acid or a collection of isolated nucleic acids comprising at least one nucleic acid sequence encoding at least one antigen-binding fragment of an antigen-binding construct according to the present invention.
[0035] In one aspect, the invention provides a vector or a collection of vectors comprising one or more of the nucleic acids or collections of nucleic acids described herein.
[0036] In one aspect, the invention provides an isolated cell comprising a nucleic acid or a collection of nucleic acids as described herein, or a vector or a collection of vectors as described herein.
[0037] In one aspect, the invention provides a method for preparing an antigen-binding construct as described herein, comprising culturing a host cell under conditions suitable for expressing the antigen-binding construct, wherein the host cell comprises a nucleic acid encoding an antigen-binding construct as described herein, or a vector or vector collection as described herein; and purifying the construct.
[0038] In another aspect, the present invention provides a method of treating a subject having a HER2-expressing tumor, comprising administering to the subject a therapeutically effective amount of an antigen-binding construct as described herein or a pharmaceutical composition as described herein.
[0039] In another aspect, the present invention provides a method for killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells, which comprises contacting the tumor cells with the antigen-binding construct described herein.
[0040] In another aspect, the present invention provides a method of inhibiting, reducing or blocking HER2 signaling in a cell, comprising administering to the cell an effective amount of an antigen binding construct as described herein or a pharmaceutical composition as described herein.
[0041] In another aspect, the present invention provides a method for detecting or measuring HER2 in a sample, comprising contacting the sample with an antigen binding construct according to the present invention and detecting or measuring the bound complex.
[0042] In yet another aspect, the present invention provides a method for enhancing the aggregation resistance of an antigen-binding construct, wherein the antigen-binding construct comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, and the first antigen-binding fragment is a scFv; the method comprises: modifying the antigen-binding construct so that the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 Glycan profiling of the anti-HER2 bispecific antibody Expi Her2-2;
[0044] Figure 2 Glycan profiling of the anti-HER2 bispecific antibody 23C2 Her2-2;
[0045] Figure 3 The killing rate of trastuzumab and pertuzumab combined with anti-HER2 bispecific antibody on BT474 tumor cells;
[0046] Figure 4 is the killing rate of trastuzumab, combined trastuzumab and pertuzumab, T-DM1, and anti-HER2 bispecific antibody against NCI-N87 tumor cells;
[0047] Figure 5 is the killing rate of trastuzumab, combined trastuzumab and pertuzumab, T-DM1, and anti-HER2 bispecific antibody against JIMT-1 tumor cells;
[0048] Figure 6 The proliferation inhibition of BT474 tumor cells by trastuzumab, the combination of trastuzumab and pertuzumab, and anti-HER2 bispecific antibody;
[0049] Figure 7 The effects of the combined use of trastuzumab and pertuzumab, and anti-HER2 bispecific antibody on the changes in tumor volume in the gastric cancer N87 mouse xenograft model;
[0050] Figure 8The effects of the combined use of trastuzumab and pertuzumab, as well as anti-HER2 bispecific antibodies, on the weight changes of mice during the efficacy of gastric cancer N87 mouse xenografts;
[0051] Fig. 9 The structures of some exemplary anti-HER2 bispecific antibodies; wherein the dimeric Fc is depicted with one chain shown in black (the first Fc polypeptide) and the other chain shown in gray (the second Fc polypeptide), the first antigen-binding fragment is scFv, which is fused to the first Fc polypeptide, and the second antigen-binding fragment is Fab, which is fused to the second Fc polypeptide. DETAILED DESCRIPTION
[0052] the term
[0053] The term "antigen binding construct" refers to any agent capable of binding to an antigen, such as a polypeptide or polypeptide complex. In some aspects, an antigen binding construct is a polypeptide that specifically binds to a target antigen. An antigen binding construct can be a monomer, dimer, multimer, protein, peptide, or protein or peptide complex; an antibody or its antigen binding portion; scFv, etc. An antigen binding construct can be a monospecific, bispecific, or multispecific polypeptide construct. In some aspects, an antigen binding construct can include, for example, one or more antigen binding components (e.g., Fab or scFv) connected to one or more Fcs. Other examples of antigen binding constructs are described below and provided in the Examples.
[0054] The term "bispecific" is intended to describe any reagent, such as an antigen-binding construct, comprising two antigen-binding portions (e.g., antigen-binding fragments), each of which has a unique binding specificity. For example, a first antigen-binding fragment binds to an epitope on a first antigen, while a second antigen-binding fragment binds to an epitope on a second antigen. For another example, the first antigen-binding fragment and the second antigen-binding fragment bind to different epitopes of the same antigen, respectively.
[0055] "Antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), multifunctional antibodies, and antibody fragments so long as they possess the desired biological activity.
[0056] The term "variable region" refers to the domain of about 100 to 110 or more amino acids defined by the N-terminal domain of the light or heavy chain of an antibody that is primarily responsible for antigen recognition. The terms light chain variable region (VL) and heavy chain variable region (VH) refer to these light chain and heavy chain domains, respectively.
[0057] The term "CDR" (complementarity determining region), also known as "hypervariable region", refers to each region of an antibody variable domain that is highly variable in sequence and / or forms a structurally defined loop. A natural four-chain antibody typically comprises six CDRs, three in the heavy chain variable region and three in the light chain variable region.
[0058] The term "Fab" refers to a constant domain containing the light chain (CL) and the first constant domain (CH1) of the heavy chain together with the variable domains VL (light chain variable region) and VH (heavy chain variable region) on the light chain and heavy chain, respectively. The variable domains contain the complementarity determining regions (CDRs) involved in antigen binding.
[0059] The term "scFv" includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In some embodiments, the scFv further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
[0060] The term "ECD" refers to the extracellular domain. The extracellular domain of HER2 includes four domains, namely ECD1, ECD2, ECD3 and ECD4.
[0061] Trastuzumab (generic name Trastuzumab) is a recombinant humanized monoclonal antibody that selectively acts on ECD4 of human epidermal growth factor receptor-2 (HER2) and can be used to treat HER2-positive cancers. An example of trastuzumab is sold under the trade name Marketed therapeutic monoclonal antibody products.
[0062] "Pertuzumab" (generic name Pertuzumab) is a recombinant humanized monoclonal antibody that selectively acts on ECD2 of human epidermal growth factor receptor-2 (HER2) and can be used to treat HER2-positive cancers.
[0063] The term "HER2" refers to the second member of the EGFR family that has tyrosine kinase activity.
[0064] The term "operably linked" refers to a functional connection between two or more peptides or polypeptide domains or nucleic acid (e.g., DNA) segments. In the context of proteins, antibodies or other polypeptides, the term "operably linked" refers to two or more amino acid segments being linked to produce a functional polypeptide.
[0065] The term "EC50" refers to the effective concentration that causes a 50% maximal response of an antigen-binding construct. As used herein, the term "IC50" refers to the inhibitory concentration that causes a 50% maximal response of an antigen-binding construct. Both EC50 and IC50 can be measured by ELISA or FACS analysis or any other method known in the art.
[0066] The term "KD" as used herein refers to the equilibrium dissociation constant, expressed as a molar concentration (M). The KD value of an antigen-binding construct can be determined using methods known in the art. A preferred method for determining the KD of an antigen-binding construct is to use surface plasmon resonance, more preferably using a biosensor system, such as a Biacore system.
[0067] The term "treat" refers to the use of measures in order to cure, heal, alleviate, relieve, alter, remedy, improve, ameliorate or affect a condition (e.g., a disease), symptoms of a condition, or prevent or delay the onset of symptoms, complications, biochemical markers, or otherwise arrest or inhibit the further development of a disease, condition or disorder in a statistically significant manner.
[0068] The term "therapeutically effective amount" refers to the amount of an antigen binding construct or composition necessary to provide a therapeutic and / or prophylactic benefit to a subject.
[0069] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. Preferably, the subject according to the present invention is a human. Unless otherwise indicated, the terms "patient" or "subject" can be used interchangeably.
[0070] As used herein, "about" means within the acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation as practiced in the art. Alternatively, "about" may mean a range of up to 5% (i.e., ±5%), such as fluctuations within ±2%, within ±1%, or within ±0.5% of the specific numerical range given. When a specific value is given in the application or claims, unless otherwise indicated, the meaning of "about" should be considered to be within an acceptable error range for that specific value.
[0071] The term "identity" is also called consistency. The percentage identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions × 100), wherein the number of gaps and the length of each gap that need to be introduced to produce the optimal alignment of the two sequences need to be considered. As shown in the following non-limiting examples, a mathematical algorithm can be used to complete the comparison of sequences and the determination of the percentage identity between two sequences. The percentage identity between two amino acid sequences can be determined using the algorithm of E.Meyers and W.Miller (Comput.Appl.Biosci., 4:11-17 (1988)), which has been incorporated into the ALIGN program (version 2.0), which uses the PAM120 residue weight table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity of two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. 484-453 (1970)), which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either the Blossum 62 matrix or the PAM250 matrix, a gap weight of 16, 14, 12, 10, 8, 6 or 4, and a length weight of 1, 2, 3, 4, 5 or 6.
[0072] The term "Xn" is equivalent to "Xaa" and refers to an unspecified amino acid, and its scope is specified by the subsequent definition in the relevant expression.
[0073] Herein, unless otherwise specified, the term "include" or its equivalents (such as contains, includes, etc.) are open terms, meaning including but not limited to the specified elements, steps or components, and are open to unspecified elements, steps or components.
[0074] Herein, unless otherwise stated, singular terms include plural referents and vice versa.
[0075] For the purpose of description and disclosure, all patents, patent applications and other confirmed publications are expressly incorporated herein by reference. These publications are provided only because they are disclosed earlier than the application date of the present application. All statements about the dates of these documents or the statements of the contents of these documents are based on the information available to the applicant and do not constitute any recognition of the correctness of the dates of these documents or the contents of these documents. Moreover, in any country, any reference to these publications in this article does not constitute an approval of the common general knowledge that the publication has become a part of this area. Various aspects of the present invention will be described in further detail in the following subsections.
[0076] Antigen Binding Constructs
[0077] The present invention provides an antigen-binding construct, which comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system (in some instances, the amino acid after the mutation at position 30 is E), or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system (in some instances, the amino acid after the mutation at position 53 is Y).
[0078] In some embodiments, the antigen-binding constructs herein further comprise a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells.
[0079] In some embodiments, the antigen-binding constructs provided herein comprise an immunoglobulin domain operably linked to a first antigen-binding fragment or / and a second antigen-binding fragment, such as one or more of the CL region, CH1 region, CH2 region, and / or CH3 region of an antibody.
[0080] In some embodiments, the antigen binding constructs provided herein comprise a constant region operably linked to the first antigen binding fragment or / and the second antigen binding fragment. The constant region can be a native sequence constant region of an immunoglobulin or a mutated constant region, such as one or more of a native or mutated CL, CH1, CH2, and / or CH3 functional domain, in some instances, these functional domains are operably linked by conventional means in the art. The constant region can be derived from a constant region of a human immunoglobulin, such as from IgG1, IgG2, IgG3, or IgG4. In some instances, the constant region can be modified to improve its ability to mediate effector functions.
[0081] In some embodiments, the antigen-binding constructs provided herein include immunoglobulin domains or skeletons, such as Fc, that are operably linked to the first antigen-binding fragment or / and the second antigen-binding fragment. The term Fc includes native sequence Fc regions and variant Fc regions. Fc can be human Fc, such as derived from IgG1, IgG2, IgG3 or IgG4. Fc can have modifications to improve its ability to mediate effector functions, for example, in some embodiments, the skeleton has modifications such as knob into hole, H435R, Y436F, de-fucose, etc.
[0082] The antigen-binding constructs provided herein can be monovalent, bivalent, or multivalent; can be monospecific, bispecific, or multispecific. In some embodiments, the antigen-binding constructs provided herein are antibodies.
[0083] Unexpected discovery, the variable region of the first antigen-binding fragment of the scFV form of the antigen-binding construct introduces mutations, can reduce the aggregation of the antigen-binding construct. These mutations can be, for example, the 30th (Kabat numbering) amino acid mutation of the heavy chain variable region of the first antigen-binding fragment to negatively charged glutamic acid (E), or the 53rd (Kabat numbering) amino acid mutation of the light chain variable region of the first antigen-binding fragment to uncharged tyrosine (Y), or the introduction of these two mutations at the same time. In addition, the inventors found that the first antigen-binding fragment of the scFV form of the original unmutated (non-E at the 30th or / and non-Y at the 53rd) is directly constructed into a bispecific antigen-binding construct, which will give its undesirable aggregation performance to the dual-characteristic antigen-binding construct, and after introducing the mutations described herein in the scFV, the constructed bispecific antibody exhibits excellent anti-aggregation. In some embodiments, the introduction of mutations does not significantly reduce the affinity of the antigen-binding construct (e.g., monospecific, bispecific antigen-binding construct) to the HER2 antigen. In some embodiments, the antigen-binding construct has good affinity to the HER2 antigen. In some embodiments, bispecific antigen-binding constructs (23C2 Her2-2, etc.) exhibit a higher binding affinity than trastuzumab and pertuzumab to the antigen Her2. In some embodiments, the KD of the antigen-binding construct to the Her2 antigen is about 1E-8M or less, about 1E-9M or less, about 6.11E-10M or less, about 1E-11M or less, or about 1E-11M or less. In some embodiments, the Her2 antigen is a human Her2 antigen. In some embodiments, the binding affinity KD of the antigen-binding construct provided herein is measured by Biacore.
[0084] In some embodiments, the antigen-binding constructs herein also exhibit excellent anti-tumor properties such as killing tumor cells, inhibiting tumor growth, etc. In some embodiments, the antigen-binding constructs constructed herein exhibit good lethality to a variety of tumor cells and cells with different expression levels of a variety of HER2. For example, some antigen-binding constructs exhibit good lethality to BT474 (Her2+++) tumor cells; some antigen-binding constructs exhibit good lethality to NCI-N87 (Her2++) tumor cells; some antigen-binding constructs exhibit good lethality to trastuzumab-resistant tumor cells (e.g., JIMT-1); and some antigen-binding constructs exhibit good lethality to tumor cells with low expression of Her2 (e.g., MCF-7Her2 0 / +).
[0085] In some embodiments, it is found through mouse model experiments that the antigen-binding constructs herein have no obvious toxic effects.
[0086] Bispecific antigen-binding constructs
[0087] Provided herein are bispecific antigen-binding constructs that bind to HER2. Bispecific antigen-binding constructs include two antigen-binding fragments, each of which binds to a specific domain or epitope of HER2.
[0088] The antigen-binding constructs provided herein are bispecific antigen-binding constructs comprising a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, and a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells;
[0089] Wherein, the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0090] In some embodiments, the antigen-binding constructs provided herein are bispecific antigen-binding constructs, wherein the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E.
[0091] In some embodiments, the antigen-binding constructs provided herein are bispecific antigen-binding constructs, wherein the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0092] In some embodiments, the antigen-binding constructs provided herein are bispecific antigen-binding constructs, wherein the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E; and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0093] In some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the amino acid before the mutation is non-E; in some embodiments, the amino acid before the mutation is K, that is, in some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system.
[0094] In some embodiments, the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the amino acid before the mutation is non-Y; in some embodiments, the amino acid before the mutation is F, that is, in some embodiments, the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system.
[0095] In some embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, wherein the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 comprise amino acid sequences that are at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the amino acid sequences of SEQ ID NOs: 27, 28, and 29, respectively. In some specific embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, wherein the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, and the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively.
[0096] In some embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, wherein the first antigen-binding fragment comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2, and the light chain CDR3 comprise amino acid sequences that are at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the amino acid sequences of SEQ ID NOs: 30, 34, and 32, respectively. In some specific embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, wherein the first antigen-binding fragment comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, and the light chain CDR1, light chain CDR2 and light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively.
[0097] In some embodiments, the antigen-binding construct herein is a bispecific antigen-binding construct, wherein the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 comprise the same heavy chain CDR1 as described in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, The amino acid sequences of NOs: 27, 28 and 29 have at least 80% identity, at least 81% identity, at least 82% identity, at least 83% identity, at least 84% identity, at least 85% identity, at least 86% identity, at least 87% identity, at least 88% identity, at least 89% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity or at least 99% identity, and the light chain CDR1, light chain CDR2 and light chain CDR3 comprise the same amino acid sequences as those of SEQ ID NOs: 27, 28 and 29, respectively. The amino acid sequences of IDNOs: 30, 34 and 32 have amino acid sequences that are at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical or at least 99% identical. In some embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, wherein the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28, and 29, respectively, and the light chain CDR1, the light chain CDR2, and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34, and 32, respectively. In some examples, the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3 according to SEQ ID NOs: 43, 28, 29, 30, 31, and 32, respectively. In some examples, the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3 according to SEQ ID NOs: 43, 28, 29, 30, 33 and 32, respectively.In some examples, the first antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3 according to SEQ ID NOs: 44, 28, 29, 30, 31, and 32, respectively. In some embodiments, the antigen-binding construct herein is a bispecific antigen-binding construct, wherein the first antigen-binding fragment comprises a mutant of the heavy chain variable region of trastuzumab and a light chain variable region of trastuzumab, wherein the mutant of the heavy chain variable region comprises a K30E mutation according to the Kabat numbering system.
[0098] In some embodiments, the antigen-binding construct herein is a bispecific antigen-binding construct, wherein the first antigen-binding fragment comprises a heavy chain variable region of trastuzumab and a mutant of a light chain variable region of trastuzumab, wherein the mutant of the light chain variable region comprises a F53Y mutation according to the Kabat numbering system.
[0099] In some embodiments, the antigen-binding construct herein is a bispecific antigen-binding construct, wherein the first antigen-binding fragment comprises a mutant of the heavy chain variable region of trastuzumab and a mutant of the light chain variable region of trastuzumab, the mutant of the heavy chain variable region comprises a K30E mutation, and the mutant of the light chain variable region comprises a F53Y mutation.
[0100] The first antigen-binding fragment is a scFV, comprising a heavy chain variable region and a light chain variable region. In some embodiments, the heavy chain variable region is the heavy chain variable region of trastuzumab or a mutant thereof, and the light chain variable region is the light chain variable region of trastuzumab or a mutant thereof.
[0101] In some embodiments, the antigen-binding constructs herein are bispecific antigen-binding constructs, and the heavy chain variable region and light chain variable region of the first antigen-binding fragment comprise an amino acid sequence having at least 80% identity, at least 85% identity, at least 86% identity, at least 87% identity, at least 88% identity, at least 89% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity with the amino acid sequences according to SEQ ID NOs: 41 and 42, respectively. In some embodiments, the first antigen-binding fragment comprises any of the CDR region sequence features described herein above. In some embodiments, the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 41 and 42, respectively. In some embodiments, the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region comprise an amino acid sequence according to SEQ ID NOs: 35 and 36, respectively. In some embodiments, the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region comprise an amino acid sequence according to SEQ ID NOs: 35 and 39, respectively. In some embodiments, the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region comprise an amino acid sequence according to SEQ ID NOs: 40 and 36, respectively.
[0102] In some embodiments, the heavy chain variable region and the light chain variable region of the first antigen binding fragment are connected by a linker to form a scFV. The linker can be any suitable, for example, charged and / or flexible linker. In a specific embodiment, the linker consists of 1 to 50 amino acids connected by peptide bonds, wherein the amino acids can be selected from 20 naturally occurring amino acids; in a more preferred embodiment, 1 to 50 amino acids are selected from glycine, alanine, proline, asparagine, glutamine and lysine; even more preferably, the linker consists of most of the sterically unhindered amino acids (such as glycine and alanine). A particularly useful flexible linker is (GGGGS)n (also referred to as (G4S)n). In some embodiments, n is any number between 1-10, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, or any range defined by any two of the foregoing numbers, such as 1-5, 2-5, 3-6, 2-4, 1-4, etc. In some specific embodiments, the linker contains a flexible connecting peptide with a sequence of GGSGGSGGSGGSGG (SEQ ID NO: 52). In some specific embodiments, the linker contains a flexible connecting peptide with a sequence of GGGGSGGGGSGGGGS (SEQ ID NO: 53). In some specific embodiments, the linker contains a flexible connecting peptide with a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 54). In some specific embodiments, the linker contains a flexible connecting peptide with a sequence of GGGPGKR (SEQ ID NO: 55). Examples of other suitable linkers also include those disclosed in Table 4 of patent application WO2019195535.
[0103] In some embodiments, the antigen-binding construct described herein is a bispecific antigen-binding construct, wherein the VH and VL of the first antigen-binding fragment are arranged from N-terminus to C-terminus in the following order: VH-linker-VL. In some embodiments, the VH and VL of the first antigen-binding fragment are arranged from N-terminus to C-terminus in the following order: VL-linker-VH.
[0104] In some embodiments, the antigen-binding construct described herein is a bispecific antigen-binding construct, wherein the second antigen-binding fragment is a Fab. The second antigen-binding fragment specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells.
[0105] In some embodiments, the second antigen-binding fragment comprises the heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 of Pertuzumab. In some embodiments, the second antigen-binding fragment comprises the light chain CDR1, light chain CDR2, and light chain CDR3 of Pertuzumab. In some embodiments, the second antigen-binding fragment comprises the heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, and light chain CDR3 of Pertuzumab. The amino acid sequences of the heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2 and light chain CDR3 of pertuzumab are: GFTFTDYTMD (SEQ ID NO: 45), DVNPNSGGSIYNQRFKG (SEQ ID NO: 46), NLGPSFYFDY (SEQ ID NO: 47), KASQDVSIGVA (SEQ ID NO: 48), SASYRYT (SEQ ID NO: 49), QQYYIYPYT (SEQ ID NO: 50), respectively.
[0106] In some embodiments, the second antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of Pertuzumab. In some embodiments, the second antigen-binding fragment is a Fab fragment of Pertuzumab. The amino acid sequence of the heavy chain variable region of Pertuzumab is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 38.
[0107] In some embodiments, the antigen-binding constructs described herein are bispecific antigen-binding constructs comprising a constant region. In some embodiments, the constant region is connected to the first antigen-binding fragment and the second antigen-binding fragment via a linker. In some embodiments, the constant region is directly connected to the first antigen-binding fragment and the second antigen-binding fragment.
[0108] In some embodiments, the antigen-binding constructs described herein are bispecific antigen-binding constructs comprising a skeleton. In some embodiments, the skeleton is connected to the first antigen-binding fragment and the second antigen-binding fragment via a linker polypeptide (e.g., an immunoglobulin hinge region polypeptide selected from the hinge region of IgG1, IgG2, or IgG4). In some embodiments, the skeleton is directly connected to the first antigen-binding fragment and the second antigen-binding fragment.
[0109] In some embodiments, the backbone is a dimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide. Fc herein is used to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of a constant region, and the Fc polypeptide of a dimeric Fc refers to one of the two polypeptides forming a dimeric Fc domain, i.e., a polypeptide that contains the C-terminal constant region of an immunoglobulin heavy chain and is capable of stabilizing self-association. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system. For example, the Fc polypeptide of a dimeric IgG Fc comprises IgG CH2 and IgG CH3 constant domain sequences. The CH3 domain comprises two CH3 sequences, one from the first Fc polypeptide and the second Fc polypeptide, respectively, and the CH2 domain comprises two CH2 sequences, one from the first Fc polypeptide and the second Fc polypeptide, respectively. In some embodiments, the first antigen binding fragment is operably connected to the first Fc polypeptide, and the second antigen binding fragment is operably connected to the second Fc polypeptide. In some embodiments, the first antigen binding fragment is operably connected to the first Fc polypeptide via a first polypeptide linker, and the second antigen binding fragment is operably connected to the second Fc polypeptide via a second polypeptide linker. The first linker polypeptide and the second linker polypeptide can form a covalent bond, such as a disulfide bond, with each other. In some embodiments, the first linker polypeptide or / and the second linker polypeptide comprise a hinge region of IgG1; in some embodiments, the first linker polypeptide or / and the second linker polypeptide comprise a hinge region of IgG2; in some embodiments, the first linker polypeptide or / and the second linker polypeptide comprise a hinge region of IgG3; in some embodiments, the first linker polypeptide or / and the second linker polypeptide comprise a hinge region of IgG4.
[0110] In some embodiments, the dimeric Fc is the Fc of human IgG1. In some embodiments, the dimeric Fc is the Fc of human IgG4.
[0111] In some embodiments, the dimeric Fc has modifications. In some embodiments, the dimeric Fc has H435R or / and Y436F, and the modification can be on any polypeptide chain of the first Fc polypeptide and the second Fc polypeptide. In some specific embodiments, the dimeric Fc has H435R or / and Y436F, and the modification occurs only on one Fc polypeptide, but not on the other Fc polypeptide. In some embodiments, the dimeric Fc has knob-into-hole mutation sites, such as Y349C, T366S, L368A, Y407V, S354C and T366W. In some embodiments, one chain of the dimeric Fc has T366Y / W or / and S354C, and the other chain has Y407T / V, Y349C, T366S or / and L368A.
[0112] In some embodiments, the dimeric Fc does not contain fucose.
[0113] In some embodiments, the antigen-binding constructs herein are glycosylated.
[0114] In some embodiments, the antigen-binding constructs herein are non-fucosylated. Defucosylation can improve the interaction between IgG1 and FcgRIIIa, thereby enhancing the ADCC effect of the antibody. Methods for generating antigen-binding constructs with little or no fucose on Fc glycosylation sites without changing the amino acid sequence are known in the art, such as adjusting the composition of the culture medium in which the expressing cells are located, or knocking out fucose expression-related genes such as FUT8 of the expressing cells.
[0115] In some embodiments, the bispecific antigen-binding constructs provided herein are bivalent.
[0116] Table S1 exemplifies bispecific antigen-binding constructs. In some embodiments, the bispecific antigen-binding constructs herein are bispecific antibodies. Table S2 exemplifies bispecific antibodies, such as Expi Her2-2, Expi Her2-3, Expi Her2-4, 23C-HER2-2, 23C-HER2-3, 23C-HER2-4, and the sequences of the CDR regions and variable regions are provided in Table S2. An exemplary bispecific antibody comprises two heavy chains and one light chain, the amino acid sequence of the heavy chain of Expi Her2-2 and 23C-HER2-2 is shown in SEQ ID NO: 11 and SEQ ID NO: 13, and the amino acid sequence of the light chain is shown in SEQ ID NO: 15; the amino acid sequence of the heavy chain of Expi Her2-3 and 23C-HER2-3 is shown in SEQ ID NO: 21 and SEQ ID NO: 13, and the amino acid sequence of the light chain is shown in SEQ ID NO: 15; the amino acid sequence of the heavy chain of Expi Her2-4 and 23C-HER2-4 is shown in SEQ ID NO: 23 and SEQ ID NO: 13, and the amino acid sequence of the light chain is shown in SEQ ID NO: 15.
[0117] Also provided herein are some ADCC-enhanced bispecific antigen-binding constructs.Exemplary ADCC-enhanced bispecific antibodies such as 23C-HER2-2, 23C-HER2-3, 23C-HER2-4 are provided herein.
[0118] Table S1: Exemplary bispecific antigen-binding constructs
[0119]
[0120]
[0121] Table S2: CDR and variable region sequences of exemplary bispecific antibodies
[0122]
[0123]
[0124] Monospecific antigen-binding constructs
[0125] A monospecific antigen-binding construct refers to an antigen-binding construct that has one binding specificity.
[0126] In some embodiments, the antigen-binding construct provided herein is a monospecific antigen-binding construct, which is a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0127] In some embodiments, the antigen-binding construct provided herein is a monospecific antigen-binding construct that is bivalent and comprises two first antigen-binding fragments of the ECD4 antigen that monovalently and specifically bind to HER2 on HER2-expressing cells.
[0128] In some embodiments, the antigen-binding constructs provided herein are monospecific antigen-binding constructs, the first antigen-binding fragment of which may adopt the sequence characteristics of the first antigen-binding fragment of the bispecific antigen-binding constructs described herein above.
[0129] In some embodiments, the antigen binding constructs provided herein are monospecific antigen binding constructs that are bivalent and comprise an Fc operably linked to a first antigen binding fragment. In some embodiments, the Fc is the Fc of human IgG1.
[0130] In some embodiments, the antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO:3.
[0131] In some embodiments, the antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO:9.
[0132] In some embodiments, the antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO:51.
[0133] Composition
[0134] Provided herein is a pharmaceutical composition comprising an antigen binding construct, or a nucleic acid encoding the antigen binding construct, and further comprising one or more pharmaceutically acceptable carriers. In some embodiments, the composition comprises one or more of a bispecific antibody such as Expi Her2-2, Expi Her2-3, Expi Her2-4, 23C-HER2-2, 23C-HER2-3, 23C-HER2-4, and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, for example, excipients, diluents, encapsulating materials, fillers, buffers or other agents.
[0135] In the composition, the antigen-binding construct may be completely afucosylated (meaning that it does not contain detectable fucose) or it may be partially afucosylated, in some embodiments, about 20% or less, about 18% or less, about 16% or less, about 14% or less, about 12% or less, about 10% or less, about 8% or less, about 6% or less, about 5% or less, about 3% or less, about 2% or less, about 1.5% or less, about 1% or less, about 0.9% or less, about 0.8% or less, about 0.7% or less, about 0.6% or less, about 0.5% or less, about 0.4% or less, about 0.3% or less, about 0.2% or less, about 0.1% or less, or about 0% of the antigen-binding construct is free of fucose. In some embodiments, about 0 to about 20%, about 0 to about 18%, about 0 to about 16%, about 0 to about 14%, about 0 to about 12%, about 0 to about 10%, about 0 to about 8%, about 0 to about 6%, about 0 to about 5%, about 0 to about 3%, about 0 to about 2%, about 0 to about 1.5%, about 0 to about 1%, about 0 to about 0.9%, about 0 to about 0.8%, about 0 to about 0.7%, about 0 to about 0.6%, about 0 to about 0.5%, about 0 to about 0.4%, about 0 to about 0.3%, about 0 to about 0.2%, about 0 to about 0.1%, or about 0.5% to about 0.6% of the antigen binding constructs do not contain fucose.
[0136] Isolated nucleic acids
[0137] Provided herein is an isolated nucleic acid or an isolated nucleic acid set, which comprises at least one nucleic acid sequence encoding at least one polypeptide of an antigen-binding construct described herein. In some embodiments, the nucleic acid encodes the sequence of an antigen-binding construct described herein. In some embodiments, the nucleic acid can encode the amino acid sequence of the first antigen-binding fragment or / and the second antigen-binding fragment of the antigen-binding construct described herein. In other embodiments, the nucleic acid can encode the amino acid sequence of the heavy chain or / and the light chain of the antigen-binding construct described herein. The nucleic acid sequences of the antigen-binding fragment, the heavy chain and the light chain of some antigen-binding constructs, such as bispecific antibodies, are exemplarily listed in the sequence table.
[0138] Carrier
[0139] The present invention provides a vector or vector set comprising one or more of the isolated nucleic acids or nucleic acid sets. In some embodiments, the vector is a cloning vector; in other embodiments, the vector is an expression vector.
[0140] The expression vector may be any expression vector capable of expressing the antigen-binding construct described herein.
[0141] Host cells
[0142] In some embodiments, provided herein is a host cell comprising the vector, the host cell being a suitable host cell for cloning or encoding an antigen-binding construct. In some embodiments, the host cell is a prokaryotic cell. In other embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is selected from yeast cells, mammalian cells, or other cells suitable for preparing antigen-binding constructs. Mammalian cells are, for example, Chinese hamster (CHO) ovary cells, CHO-S cells.
[0143] Methods of preparing antigen-binding constructs
[0144] In some embodiments, provided herein is a method for preparing an antigen-binding construct, the method comprising: culturing a host cell containing a nucleic acid encoding the antigen-binding construct under conditions suitable for expression of the antigen-binding construct, and recovering the antigen-binding construct from the host cell or host cell culture medium. In order to produce the antigen-binding construct, the nucleic acid encoding the antigen-binding construct is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. The nucleic acid can be obtained by various methods known in the art, such as gene splicing, chemical synthesis, and cloning.
[0145] use
[0146] Provided herein are uses of antigen binding constructs. In specific embodiments, the antigen binding construct used may be Expi Her2-2, Expi Her2-3, Expi Her2-4, 23C-HER2-2, 23C-HER2-3, 23C-HER2-4.
[0147] In some embodiments, administering a therapeutically effective amount of the antigen-binding construct herein to a subject can kill HER2-expressing tumor cells or inhibit the growth of HER2-expressing tumor cells. In some embodiments, provided herein is the use of an antigen-binding construct in the preparation of a drug for killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells. In some embodiments, provided herein is an antigen-binding construct for killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells. In some embodiments, the present invention provides a therapeutic agent for killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells, which comprises an antigen-binding construct described herein as an active ingredient.
[0148] In some embodiments, a therapeutically effective amount of the antigen-binding construct herein is administered to a subject, and HER2-expressing tumors can be treated. Subjects in need of treatment include those who have already suffered from a disease or condition, subjects at risk of developing a disease or condition, and subjects who may suffer from a disease or condition and whose purpose is to prevent, delay or weaken a disease or condition. In some embodiments, provided herein is the use of the antigen-binding construct in the preparation of a drug for treating a subject with a HER2-expressing tumor. In some embodiments, provided herein is an antigen-binding construct for treating a HER2-expressing tumor. In some embodiments, provided herein is a therapeutic agent for treating a HER2-expressing tumor, which comprises an antigen-binding construct as described herein as an active ingredient. Examples of tumors include, but are not limited to, biliary cancer, carcinosarcoma, esophageal cancer, gastroesophageal junction cancer, breast cancer, gastric cancer, pancreatic cancer, head and neck cancer, colorectal cancer, renal cancer, cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, malignant melanoma, pharyngeal cancer, oral cancer or skin cancer.
[0149] In certain embodiments, the tumor is HER2 0-1+, 1+, HER2 2+, or HER2 3+ as determined by IHC. In some embodiments, the tumor is HER2 2+ or lower, or HER2 1+ or lower.
[0150] In some embodiments, an effective amount of an antigen-binding construct is administered to a cell to inhibit, reduce or block HER2 signaling in the cell. In some embodiments, provided herein is the use of an antigen-binding construct in the preparation of a drug for inhibiting, reducing or blocking HER2 signaling in a cell. In some embodiments, provided herein is an antigen-binding construct for inhibiting, reducing or blocking HER2 signaling in a cell. In some embodiments, provided herein is a therapeutic agent for inhibiting, reducing or blocking HER2 signaling in a cell, comprising an antigen-binding construct as described herein as an active ingredient. In some embodiments, the cell is a tumor cell.
[0151] In some embodiments, a method of detecting or measuring HER2 in a sample is provided, comprising contacting the sample with an antigen binding construct described herein and detecting or measuring the bound complex.
[0152] Methods for enhancing aggregation resistance of antigen binding constructs
[0153] Provided herein is a method for enhancing the aggregation resistance of an antigen-binding construct, wherein the antigen-binding construct comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, and the first antigen-binding fragment is a scFv; the method comprises: modifying the antigen-binding construct so that the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0154] In some embodiments, the antigen-binding constructs herein further comprise a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells; the second antigen-binding fragment is a Fab. In some embodiments, the first antigen-binding fragment comprises a group of CDRs selected from the following:
[0155] i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively;
[0156] ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively;
[0157] iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0158] iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0159] v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0160] vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0161] vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively;
[0162] viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively; or ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
[0163] In some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the amino acid before the mutation is non-E; in some embodiments, the amino acid before the mutation is K, that is, in some embodiments, the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system.
[0164] In some embodiments, the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the amino acid before the mutation is non-Y; in some embodiments, the amino acid before the mutation is F, that is, in some embodiments, the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system.
[0165] In some embodiments, the antigen-binding construct is modified so that the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system, and the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system. In some embodiments, the first antigen-binding fragment is a scFv and comprises a heavy chain variable region of trastuzumab or a mutant thereof and a light chain variable region of trastuzumab or a mutant thereof, so that the mutant of the heavy chain variable region comprises a K30E mutation, and the mutant of the light chain variable region comprises a F53Y mutation.
[0166] In some embodiments, the method also includes confirming that the modified antigen-binding construct is attached to the ability of her2 antigen. In some embodiments, the method also includes selecting the modified antigen-binding construct attached to her2 antigen. In some embodiments, the affinity (such as KD) of the antigen-binding construct is higher than or suitable with unmodified antigen-binding construct.
[0167] In some embodiments, the method further comprises selecting an antigen-binding construct that has a reduced tendency to aggregate compared to an unmodified antigen-binding construct.
[0168] Although the foregoing invention has been described in considerable detail by way of illustration and example for purposes of clear understanding, it will be apparent to one of ordinary skill in the art based on the teachings of the present invention that certain changes and modifications may be made to the present invention without departing from the spirit and scope of the appended claims. The following examples are provided by way of illustration only and are not intended to be limiting. One of ordinary skill in the art will readily recognize a variety of noncritical parameters that may be changed or modified to produce substantially similar results.
[0169] Unless otherwise indicated, the practice of the present invention will employ conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology within the technical scope of the art. Such techniques are fully explained in the literature. See, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); ALL Lehninger, Biochemistry (Worth Publishers, Inc., currently increasing); Sambrook et al., Molecular Cloning: A Laboratory Manual (1989, 2nd edition); Methods In Enzymology (S. Colowick and N. Kaplan, ed., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3rd edition (Plenum Press) Volumes A and B (1992).
[0170] The present invention also provides the following specific implementation schemes, but the protection scope of the present invention is not limited thereto:
[0171] Embodiment 1. An antigen-binding construct, comprising a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, preferably, the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, preferably, the mutated amino acid is Y.
[0172] Embodiment 2. An antigen-binding construct according to embodiment 1, wherein the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system, or / and the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system.
[0173] Embodiment 3. The antigen-binding construct of embodiment 1 or 2, which is an antibody.
[0174] Embodiment 4. The antigen-binding construct of any one of Embodiments 1-3, wherein the first antigen-binding fragment comprises a group of CDRs selected from:
[0175] i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively;
[0176] ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively;
[0177] iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0178] iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0179] v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0180] vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively;
[0181] vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively;
[0182] viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively; or
[0183] ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
[0184] Embodiment 5. An antigen-binding construct according to any one of Embodiments 1-4, wherein the first antigen-binding fragment comprises a heavy chain variable region of trastuzumab or a mutant thereof, and a light chain variable region of trastuzumab or a mutant thereof, wherein the mutant of the heavy chain variable region comprises a K30E mutation according to the Kabat numbering system, and the mutant of the light chain variable region comprises a F53Y mutation according to the Kabat numbering system.
[0185] Embodiment 6. The antigen-binding construct according to any one of embodiments 4-5, wherein the first antigen-binding fragment is selected from: i. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 41 and 42, respectively;
[0186] ii. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 41 and 42, respectively;
[0187] iii. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 35 and 36, respectively;
[0188] iv. the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 35 and 39, respectively; or
[0189] v. The first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region comprise amino acid sequences according to SEQ ID NOs: 40 and 36, respectively.
[0190] Embodiment 7. An antigen-binding construct according to any one of embodiments 1-6, wherein the VH and VL of the first antigen-binding fragment are arranged in the following order from N-terminus to C-terminus: VH-linker-VL.
[0191] Embodiment 8. The antigen-binding construct of any one of Embodiments 1-7, wherein the antigen-binding construct further comprises a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells.
[0192] Embodiment 9. The antigen binding construct of embodiment 8, wherein the second antigen binding fragment is Fab.
[0193] Embodiment 10. An antigen-binding construct according to embodiment 8 or 9, wherein the second antigen-binding fragment comprises the heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2 and light chain CDR3 of Pertuzumab.
[0194] Embodiment 11. The antigen-binding construct of Embodiment 8 or 9, wherein the second antigen-binding fragment comprises the heavy chain variable region of Pertuzumab and the light chain variable region of Pertuzumab.
[0195] Embodiment 12. An antigen-binding construct according to any one of embodiments 8-11, wherein the antigen-binding construct comprises an immunoglobulin functional domain operably linked to the first antigen-binding fragment and / or the second antigen-binding fragment, and the immunoglobulin functional domain comprises: i. CL, one or more of CH1, CH2, or CH3, or ii. Fc.
[0196] Embodiment 13. An antigen-binding construct according to Embodiment 12, wherein the CL, CH1, CH2, CH3, and Fc are derived from CL, CH1, CH2, CH3, and Fc of human IgG, respectively.
[0197] Embodiment 14. An antigen-binding construct according to Embodiment 12, wherein the CL, CH1, CH2, CH3 or Fc has a modification or has no modification; preferably, the modification of the CH3 or Fc is, for example, a substitution of the amino acid at position 435 or / and 436 according to the Kabat numbering system.
[0198] Embodiment 15. An antigen-binding construct according to embodiment 12, wherein the Fc is a dimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first antigen-binding fragment is operably linked to the first Fc polypeptide, and the second antigen-binding fragment is operably linked to the second Fc polypeptide.
[0199] Embodiment 16. The antigen-binding construct of any one of embodiments 1-15, wherein the antigen-binding construct is a bispecific antibody or a multispecific antibody.
[0200] Embodiment 17. The antigen-binding construct according to any one of embodiments 1-15, which is bivalent or multivalent.
[0201] Embodiment 18. An antigen-binding construct according to any one of embodiments 1-7, wherein the antigen-binding construct is a monospecific antibody; wherein the antigen-binding construct is monovalent, bivalent or multivalent.
[0202] Embodiment 19. The antigen-binding construct of embodiment 1, which is selected from the group consisting of:
[0203] i. The antigen-binding construct is a bivalent bispecific antibody comprising: a heavy chain comprising SEQ ID NO: 11, a heavy chain comprising SEQ ID NO: 13, and a light chain comprising SEQ ID NO: 15;
[0204] ii. the antigen-binding construct is a bivalent bispecific antibody comprising: a heavy chain comprising SEQ ID NO: 21, a heavy chain comprising SEQ ID NO: 13, and a light chain comprising SEQ ID NO: 15;
[0205] iii. the antigen-binding construct is a bivalent bispecific antibody comprising: a heavy chain comprising SEQ ID NO: 23, a heavy chain comprising SEQ ID NO: 13, and a light chain comprising SEQ ID NO: 15;
[0206] iv. the antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO: 3;
[0207] v. the antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO: 9; or
[0208] vi. The antigen-binding construct is a bivalent monospecific antibody comprising the amino acid sequence of SEQ ID NO:51.
[0209] Embodiment 20. The antigen-binding construct of any one of Embodiments 1-19, wherein the antigen-binding construct has reduced aggregation compared to an antigen-binding construct having a non-E at position 30 or / and a non-Y at position 53; or / and,
[0210] The antigen-binding construct does not significantly reduce the binding affinity to the ECD4 antigen and / or the ECD2 antigen of HER2 compared to the antigen-binding construct with non-E at position 30 and / or non-Y at position 53.
[0211] Embodiment 21. The antigen-binding construct of any one of embodiments 1-20, wherein the antigen-binding construct is afucosylated.
[0212] Embodiment 22. A pharmaceutical composition comprising the antigen-binding construct according to any one of embodiments 1-21 and a pharmaceutically acceptable carrier.
[0213] Embodiment 23. An isolated nucleic acid or a collection of isolated nucleic acids comprising at least one nucleic acid sequence encoding at least one antigen-binding fragment of an antigen-binding construct according to any one of embodiments 1-21.
[0214] Embodiment 24. A vector or a collection of vectors comprising one or more of the nucleic acids or the collection of nucleic acids according to embodiment 23.
[0215] Embodiment 25. An isolated cell comprising the nucleic acid or a collection of nucleic acids according to embodiment 23, or the vector or a collection of vectors according to claim 24.
[0216] Embodiment 26. A method for preparing an antigen-binding construct according to any one of Embodiments 1-21, comprising culturing a host cell under conditions suitable for expressing the antigen-binding construct, wherein the host cell comprises a nucleic acid encoding the antigen-binding construct, or a vector or vector collection according to Embodiment 24; and purifying the construct.
[0217] Embodiment 27. A method of treating a subject having a HER2-expressing tumor, comprising administering to the subject a therapeutically effective amount of an antigen-binding construct according to any one of Embodiments 1-21 or a pharmaceutical composition according to Embodiment 22.
[0218] Embodiment 28. The method according to Embodiment 27 comprises contacting tumor cells with the antigen-binding construct, thereby killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells.
[0219] Embodiment 29. The method of embodiment 27 or 28, wherein the tumor is biliary tract cancer, carcinosarcoma, esophageal cancer, gastroesophageal junction cancer, breast cancer, gastric cancer, pancreatic cancer, head and neck cancer, colorectal cancer, kidney cancer, cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, malignant melanoma, pharyngeal cancer, oral cancer, or skin cancer.
[0220] Embodiment 30. The method according to any one of Embodiments 27-29, comprising administering an effective amount of the antigen-binding construct or the pharmaceutical composition to a cell, thereby inhibiting, reducing or blocking HER2 signaling in the cell.
[0221] Embodiment 31. A method for enhancing the aggregation resistance of an antigen-binding construct, wherein the antigen-binding construct comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, and the first antigen-binding fragment is a scFv; the method comprises: modifying the antigen-binding construct so that the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
[0222] Embodiment 32. A method for enhancing the aggregation resistance of an antigen-binding construct according to Embodiment 31, wherein the antigen-binding construct further comprises a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells; the second antigen-binding fragment is Fab.
[0223] Embodiment 33. A method of enhancing aggregation resistance of an antigen-binding construct according to Embodiment 31 or 32, wherein the first antigen-binding fragment comprises a group of CDRs selected from:
[0224] i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NO: 27, 28, 29, respectively;
[0225] ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 27, 28, 29, respectively;
[0226] iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NO: 30, 34, 32, respectively;
[0227] iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NO: 30, 34, 32, respectively;
[0228] v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively;
[0229] vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 27, 28, 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 30, 34, 32, respectively;
[0230] vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively;
[0231] viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively;
[0232] ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively; or
[0233] ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
[0234] Embodiment 34. A method for enhancing the aggregation resistance of an antigen-binding construct according to Embodiment 31 or 32, wherein the first antigen-binding fragment is a scFv and comprises a heavy chain variable region of trastuzumab or a mutant thereof and a light chain variable region of trastuzumab or a mutant thereof, wherein the mutant of the heavy chain variable region comprises a K30E mutation, and the mutant of the light chain variable region comprises a F53Y mutation.
[0235] Example 1 Construction, expression and purification of anti-Her2-scFv-Fc and its variants
[0236] When constructing anti-Her2-scFv-Fc, the Fc part uses human IgG1, and the variable region sequence of the anti-Her2 arm is based on The sequence of the monoclonal antibody was linked to The variable regions of the light and heavy chains of the monoclonal antibody were connected in series to form anti-Her2-scFv-Fc (SEQ ID NO: 1), and its amino acid sequence is as follows:
[0237] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVS SGGGGSGGGGSGGGGSDIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTK VEIKGEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0238] In addition, point mutations were constructed on the anti-Her2-scFv-Fc sequence to construct the following variants:
[0239] anti-Her2-scFv-VL-F53Y-Fc (SEQ ID NO: 3): derived from wild-type anti-Her2-scFv-Fc, with F53Y in the VL region; its amino acid sequence is as follows:
[0240] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVS SGGGGSGGGGSGGGGSDIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASYLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTK VEIKGEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0241] anti-Her2-scFv-VL-F53A-Fc (SEQ ID NO: 5): derived from wild-type anti-Her2-scFv-Fc, with F53A in the VL region; its amino acid sequence is as follows:
[0242] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASALYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0243] anti-Her2-scFv-VL-F53R-Fc (SEQ ID NO: 7): Derived from wild-type anti-Her2-scFv-Fc, with F53R in the VL region; its amino acid sequence is as follows:
[0244] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASRLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0245] anti-Her2-scFv-VH-K30E-Fc (SEQ ID NO: 9): Derived from wild-type anti-Her2-scFv-Fc, with K30E in the VH region; its amino acid sequence is as follows:
[0246] EVQLVESGGGLVQPGGSLRLSCAASGFNIEDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVS SGGGGSGGGGSGGGGSDIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTK VEIKGEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0247] The DNA sequences of anti-Her2-scFv-Fc and its variants (SEQ ID NOs: 2, 4, 6, 8 and 10) were synthesized and cloned into pcDNA3.1 expression vector respectively. TM The expression vector of anti-Her2-scFv-Fc or its variant was transfected into ExpiCHO cells (CHO-S, Thermo company) by expression kit (Thermo Fisher, catalog number A29133). The cells were cultured in an incubator with a humidified atmosphere of 8% CO2 at 37°C in ExpiCHO expression medium and on a tracked shaking platform rotating at 130 rpm. The culture supernatant was collected and protein A magnetic beads (Genscript, catalog number L00273) were used for protein purification. The protein concentration was measured by UV-Vis spectrophotometer (NanoDrop lite, Thermo Scientific).
[0248] Table 1: Sequence information of anti-Her2-scFv-Fc and its variants
[0249]
[0250] Example 2 Aggregation verification of anti-Her2-scFv-Fc and its variants and binding detection with human Her2 antigen
[0251] The expressed and purified anti-Her2-scFv-Fc and its variants were used to measure the affinity of the test molecules to human Her2 protein by Biacore T200 (GE Company). The experimental process is described as follows:
[0252] A certain amount of anti-Her2-scFv-Fc or its variants were captured by a chip coupled with Anti-hIgG, and then the antigen human HER2 protein (Sino Biological, catalog number 10004-H08H) was passed through the chip surface, and the reaction signal was detected in real time by Biacore T200 to obtain the binding and dissociation curves. The buffer used in the experiment was Biacore universal buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4·12H2O, 1.8mM KH2PO4, 0.05% surfactant P20 (GE, catalog number BR-1000-54), pH 7.4). Anti-hIgG (source human antibody capture kit, GE, catalog number 29-2346-00) was coupled to the surface of the CM5 chip with a reaction value of about 9000RU, and anti-Her2-scFv-Fc or its variants were captured at about 200RU. Then, the signal values of the interaction between different concentrations of human HER2 protein (100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM) and anti-Her2-scFv-Fc or its variants were detected. The flow rate of the flow cell was 50μl / min, the binding time was 240s, the dissociation time was 1400s, and it was regenerated with 3M MgCl2 (GE Company) for 60s, and the baseline was stable. The results were obtained according to the affinity and kinetics 1:1 binding mode calculation in biacore evaluationsoftware. The affinity of anti-Her2-scFv-Fc or variants with antigen human Her2 protein is shown in Table 2. Compared with anti-Her2-scFv-Fc (KD = 0.77nM), variant anti-Her2-scFv-VL-F53A-Fc (KD = 1.26nM) has a greater effect on the binding affinity to the antigen human Her2 protein; variant anti-Her2-scFv-VL-F53Y-Fc (KD = 0.8nM) has a similar binding affinity to the antigen human Her2 protein as anti-Her2-scFv-Fc (KD = 0.77nM), and variant anti-Her2-scFv-VH-K30E-Fc has a binding KD of 0.54nM to the antigen human Her2 protein. It can be seen that the introduction of F53Y and K30E mutations will not reduce the binding affinity to the antigen human Her2 protein.
[0253] The components of anti-Her2-scFv-Fc or its variants were separated by gel chromatography. Neutral pH buffer was used as the mobile phase for elution, and the molecular weight components were eluted in descending order. The chromatographic column was ACQUITY UPLC Protein BEH SEC Column 1.7μm, 4.6*300mm gel chromatography column, column temperature 25℃. The mobile phase is 50mmol / L phosphate buffer-200mmol / L sodium chloride, pH 7.0 (weigh 2.33g sodium dihydrogen phosphate dihydrate, 12.53g disodium hydrogen phosphate dodecahydrate, 11.69g sodium chloride, add about 800ml ultrapure water, stir until fully dissolved, add ultrapure water to 1000ml, mix and filter through 0.22μm filter membrane). Dilute the sample to 10mg / ml with the mobile phase as the test solution, accurately measure 2μl and inject it into the liquid chromatograph (if the sample concentration is lower than 10mg / ml, adjust the injection volume to inject 20μg protein), and detect at a wavelength of 280nm. The flow rate is 0.30ml / min, and the isocratic elution is 15min. Data processing, the results are quantitatively analyzed by area normalization method. The peak area percentages of aggregates, immunoglobulin monomers and low molecular weight impurities were calculated respectively, where the aggregates were before the main peak, the immunoglobulin monomers were the main peaks, and the low molecular weight impurities were after the main peaks. The ratio of the main peak and aggregate content of anti-Her2-scFv-Fc or its variants is shown in Table 2. The variants anti-Her2-scFv-VL-F53Y-Fc and anti-Her2-scFv-VH-K30E-Fc significantly reduced the aggregates; the aggregates were reduced from 6.31% of anti-Her2-scFv-Fc to 4.94% and 3.39%, respectively.
[0254] Table 2: Aggregate content and binding affinity to antigen Her2 of anti-Her2-scFv-Fc and its variants
[0255]
[0256] Example 3 Construction, expression and purification of anti-Her2 bispecific antibody
[0257] The anti-Her2 bispecific antibody was produced as human IgG1 by Knobs-into-holes (Ridgway, et al., 1996) Fc engineering. The Fc region sequence of one of the heavy chains was designed with H435R and Y436F mutations (Jendeberg et al., 1997) to reduce the affinity of Fc for protein A, which is beneficial for removing homodimers formed during the assembly process of the bispecific antibody in protein A affinity purification (patent US5945311A). As can be seen from Example 2, the anti-Her2-scFv-VL-F53Y-Fc mutation and the anti-Her2-scFv-VH-K30E-Fc mutation can significantly reduce the anti-Her2-scFv aggregates without reducing the affinity for the Her2 antigen. In this embodiment, the antigen binding domain of one anti-Her2 arm of the anti-Her2 bispecific antibody is in the form of scFv (VH-linker-VL structure), and the variable region sequence comprises the mutation K30E (b-anti-Her2-scFv-VH-K30E-Fc, SEQ ID NO: 21), the mutation F53Y (b-anti-Her2-scFv-VL-F53Y-Fc, SEQ ID NO: 23) or both of these point mutations anti-Her2-scFv-VH-K30E-VL-F53Y-Fc (SEQ ID NO: 24). NO: 11); the antigen binding domain of the other anti-Her2 arm of the anti-Her2 bispecific antibody in this embodiment is in the form of Fab, including anti-Her2-domain2-HC-Fc (SEQ ID NO: 13) and anti-Her2-domain2-LC (SEQ ID NO: 15); in addition, an anti-Her2 bispecific antibody was constructed using scFv (VH-linker-VL structure or VL-linker-VH structure) without mutation as a control.
[0258] Table 3: Sequence information of anti-Her2 bispecific antibodies
[0259]
[0260]
[0261]
[0262]
[0263] The DNA sequences of the anti-Her2 bispecific antibodies (SEQ ID NOs: 12, 14 and 16) were synthesized and cloned into the pcDNA3.1 expression vector. TM The expression vectors of anti-Her2-scFv-VH-K30E-VL-F53Y-Fc (SEQ ID NO: 11), anti-Her2-domain2-HC-Fc (SEQ ID NO: 13) and anti-Her2-domain2-LC (SEQ ID NO: 15) were co-transfected into ExpiCHO cells at a transfection ratio of 1:1:1.5 using an expression kit (Thermo Fisher, catalog number A29133). The transfection density was 6×10 6 cells / ml. The culture medium was ExpiCHO expression medium. The cell culture supernatant was collected by centrifugation on the 10th day after transfection. Protein A magnetic beads (Genscript, catalog number L00273) were used for protein purification. The protein concentration was measured by UV-Vis spectrophotometer (NanoDrop lite, Thermo Scientific). This sample was named Expi Her2-2. Referring to this method, other bispecific antibodies Expi Her2-1, Expi Her2-3, Expi Her2-4, and Expi Her2-5 were expressed and purified according to the DNA sequences given in the table above.
[0264] Example 4 Preparation and verification of fucose knockout bispecific antibody
[0265] Knocking out the fucose expression-related gene FUT8 can increase the interaction between IgG1 and FcgRIIIa, thereby enhancing the ADCC effect of the antibody (Shields et al., 2002; Yamane-Ohnuki et al., 2004). In this example, a fucose knockout anti-Her2 bispecific antibody was prepared using FUT8-knockout CHO-S cells (named CHO FUT8- / - cells). The DNA sequences of the anti-Her2 bispecific antibody (SEQ ID NOs: 12, 14 and 16) were synthesized and cloned into the pcDNA3.1 expression vector respectively. By using High-yield expression system (Cat. No.: MIR 6270) co-transfected the expression vectors of anti-Her2-scFv-VH-K30E-VL-F53Y-Fc, anti-Her2-domain2-HC-Fc and anti-Her2-domain2-LC into FUT8-knockout CHO-S cells at a transfection ratio of 1:1:1.5. The transfection density was 6×106 cells / ml. The culture medium is Expression medium (Cat. No. MIR 6200, manufacturer Mirus). Continue to culture until the 10th day after transfection and collect the cell culture supernatant by centrifugation. Protein purification was performed using protein A magnetic beads (Genscript, catalog number L00273). The protein concentration was measured by UV-Vis spectrophotometer (NanoDrop lite, Thermo Scientific). This sample was named 23C2 Her2-2. Referring to this method, the sequences of Expi Her2-1, Expi Her2-3, Expi Her2-4, and Expi Her2-5 listed in Table 3 were expressed in CHO FUT8- / - cells, and the corresponding fucose knockout anti-Her2 bispecific antibodies 23C2 Her2-1, 23C2 Her2-3, 23C2 Her2-4, and 23C2 Her2-5 were obtained.
[0266] The anti-Her2 bispecific antibody samples expressed in CHOFUT8- / - cells and CHO-S cells were treated with the GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass., USA) to release N-glycans from the protein, and then the N-glycans were labeled and separated by chromatographic columns. The structure and content of N-glycans were obtained by analyzing them using an FLR detector (Waters, Milford, Mass., USA). The sugar profile analysis of the anti-Her2 bispecific antibody Expi HER2-2 is shown in Figure 1 Glycan profiling of anti-Her2 bispecific antibody 23C2HER2-2 expressed in FUT8 knockout CHO-S cells is shown in Figure 2 The proportion of glycoform content is shown in Table 4. The proportion of fucose-free in the normal anti-Her2 bispecific antibody Expi HER2-2 is 21.85%, and the proportion of fucose-free in the anti-Her2 bispecific antibody 23C2 HER2-2 expressed by FUT8- knockout CHO-S cells is 99.40%.
[0267] Table 4: Glycoform content analysis of anti-Her2 bispecific antibodies
[0268]
[0269] Example 5: Aggregation Verification of Bispecific Antibodies
[0270] This example relates to the aggregation verification of the anti-Her2 bispecific antibodies 23C2 Her2-1, 23C2 Her2-2, 23C2 Her2-3, 23C2 Her2-4, and 23C2Her2-5.
[0271] The anti-Her2 bispecific antibody was separated and the aggregate content was verified using a gel chromatography column. A neutral pH buffer was used as the mobile phase for elution, and the molecular weight components were eluted in descending order. The chromatographic column is ACQUITY UPLC Protein BEH SEC Column 1.7μm, 4.6*300mm gel chromatography column, column temperature 25℃. The mobile phase is 50mmol / L phosphate buffer-200mmol / L sodium chloride, pH 7.0 (weigh 2.33g sodium dihydrogen phosphate dihydrate, 12.53g disodium hydrogen phosphate dodecahydrate, 11.69g sodium chloride, add about 800ml ultrapure water, stir until fully dissolved, add ultrapure water to 1000ml, mix and filter through 0.22μm filter membrane). Dilute the sample to 10mg / ml with the mobile phase as the test solution, accurately measure 2μl and inject it into the liquid chromatograph (if the sample concentration is lower than 10mg / ml, adjust the injection volume to inject 20μg protein), and detect at a wavelength of 280nm. The flow rate is 0.30ml / min, and the isocratic elution is 15min. Data processing, the results are quantitatively analyzed by area normalization method. The peak area percentages of aggregates, immunoglobulin monomers and low molecular weight impurities were calculated respectively, wherein the peak before the main peak was the aggregates, the main peak was the immunoglobulin monomers, and the peak after the main peak was the low molecular weight impurities.
[0272] Table 5: Aggregate content of anti-Her2 bispecific antibodies
[0273] Sample name Aggregates monomer Low molecular weight fragments 23C2 Her2-2 8.51% 91.02% 0.47% 23C2 Her2-1 19.55% 80.05% 0.40%
[0274] The results showed that when scFV (without mutation) was assembled into a bispecific antibody, the bispecific antibody still produced a large amount of aggregates, while the aggregate content of the bispecific antibody could be reduced by introducing mutations. Compared with 23C2 Her2-1 without mutations, the aggregate content of 23C2 Her2-2 could be reduced to 8.51% (Table 5).
[0275] Example 6 Antigen Binding Detection of Anti-Her2 Bispecific Antibodies
[0276] The expressed and purified anti-Her2 bispecific antibody was used to measure the affinity of the test molecule to the HER2 protein by Biacore T200 (GE). The experimental process is described as follows:
[0277] A certain amount of anti-Her2 bispecific antibody was captured by a chip coupled with Anti-hIgG, and then human Her2 (Sino Biological, catalog number 10004-H08H) was passed over the chip surface, and the reaction signal was detected in real time using Biacore T200 to obtain the binding and dissociation curves. The buffer used in the experiment was Biacore universal buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4·12H2O, 1.8mM KH2PO4, 0.05% surfactant P20, pH 7.4). Anti-hIgG (source human antibody capture kit, GE, catalog number 29-2346-00) was coupled to the CM5 chip surface with a reaction value of about 9000RU, capturing anti-Her2 bispecific antibody at about 200RU, and then detecting the signal value of the interaction between Her2 protein at different concentrations (100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM) and anti-Her2 bispecific antibody. The flow rate of the flow cell was 50μl / min, the binding time was 240s, the dissociation time was 1400s, and the baseline was stable after regeneration with 3M MgCl2 (GE) for 60s.
[0278] According to the results obtained by biacore evaluation software, the binding affinity of anti-Her2 bispecific antibody 23C2Her2-2 to antigen Her2 and the control trastuzumab and pertuzumab are shown in Table 6. The binding KD of anti-Her2 bispecific antibody 23C2 Her2-2 to antigen Her2 is 6.11E-10M, the binding KD of trastuzumab to antigen Her2 is 1.22E-09M, and the binding KD of pertuzumab to antigen Her2 is 2.35E-09M. The anti-Her2 bispecific antibody 23C2Her2-2 has a higher affinity for antigen Her2 than trastuzumab and pertuzumab.
[0279] Table 6: Affinity of anti-Her2 bispecific antibodies for human Her2 antigen
[0280] Ka(1 / Ms) Kd(1 / s) KD(M) 23C2 Her2-2 1.79E+05 1.09E-04 6.11E-10 Trastuzumab control 1.73E+05 2.12E-04 1.22E-09 Pertuzumab control 1.15E+05 2.69E-04 2.35E-09
[0281] Example 7 Antigen Binding Detection of Anti-Her2 Bispecific Antibodies
[0282] Referring to the experimental process of Example 6, the affinity of the expressed and purified anti-Her2 bispecific antibodies 23C2Her2-1, 23C2 Her2-2, 23C2 Her2-3, 23C2 Her2-4, and 23C2 Her2-5 to the HER2 protein was determined by Biacore T200 (GE).
[0283] The affinity of the anti-Her2 bispecific antibody to the antigen human Her2 protein is shown in Table 7. Combining the results of Tables 6 and 7, it can be seen that the introduction of F53Y and K30E mutations can improve the binding affinity of the anti-Her2 bispecific antibody to the antigen human Her2 protein.
[0284] Table 7: Affinity of anti-Her2 bispecific antibodies for human Her2 antigen
[0285] Sample name 23C2 Her2-1 Antigen Her2 KD 4.02nM
[0286] Example 8 Killing of Her2-positive target cells BT474 by anti-Her2 bispecific antibody
[0287] NK cells were provided by human PBMC (peripheral blood mononuclear cells; effector cells) to study the killing effect of anti-Her2 bispecific antibodies on target cells (BT474 Her2+++, source: Cell Bank of Type Culture Collection Committee of Chinese Academy of Sciences), calculate EC50, and evaluate the in vitro activity of anti-Her2 bispecific antibodies.
[0288] The specific experimental process is as follows:
[0289] BT474 cells were cultured in 1640 experimental medium containing 2% FBS (fetal bovine serum) to adjust the cell density to 3×10 5 cells / ml, 50 μl per well was inoculated in a 96-well cell culture plate (eppendorf, catalog number: 0030730199). Anti-Her2 bispecific antibodies of different concentrations (1000 ng / ml, 333 ng / ml, 111 ng / ml, 37 ng / ml, 12.3 ng / ml, 4.11 ng / ml, 1.37 ng / ml, 0.46 ng / ml, 0.15 ng / ml, 0.05 ng / ml) were prepared using 1640 experimental medium, and different concentrations of antibodies were added to the above 96-well cell culture plate, 50 μl per well. Human PBMCs were adjusted to a cell density of 1.5×10 using 1640 experimental medium. 6cells / ml, 100μl per well. Set up the drug administration group (target cell + effector cell + antibody), target cell group (BT474 cells), effector cell group (human PBMC), target cell + effector cell group, blank control group (culture medium) and lysate control group, target cell maximum release group (target cell + lysate), the effector-target ratio is 10:1. 45 minutes before the test, add 20μl / well lysate (Promega, catalog number G182A) to the target cell maximum release group and lysate control group. Use after 45 minutes. The cell lysis rate (killing rate) was detected by using a non-radioactive cytotoxicity assay kit (cytotox 96 nonradioactive cytotoxicity assay, Promega, G1780).
[0290] Lysis rate (%) = (OD 给药组 -OD 靶细胞+效应细胞组 ) / (OD 靶细胞最大释放组 -OD 靶细胞组 )×100%
[0291] Figure 3 The killing rate of anti-Her2 bispecific antibody on BT474 Her2+++ tumor cells is shown. ADCC-enhanced anti-Her2 bispecific antibodies 23C2 HER2-1 and 23C2 HER2-2 were superior to the combination of trastuzumab and pertuzumab in killing BT474 tumor cells, and superior to the CHO-S expressed anti-Her2 bispecific antibodies Expi Her2-1 and Expi HER2-2; among them, the EC50 of the combination of trastuzumab and pertuzumab (1:1) was 8.627 ng / ml, the EC50 of Expi HER2-1 was 38.05 ng / ml, and Expi HER2-2 was superior to Expi HER2-1, with an EC50 of 35.17 ng / ml; the EC50 of ADCC-enhanced 23C2 HER2-1 was 4.728 ng / ml, and the ADCC-enhanced 23C2 HER2-2 was superior to 23C2HER2-1, with an EC50 of 3.658 ng / ml.
[0292] Example 9 Killing of Her2-positive target cells NCI-N87 by anti-Her2 bispecific antibody
[0293] NK cells were provided by human PBMC (peripheral blood mononuclear cells; effector cells) to study the killing effect of anti-Her2 bispecific antibodies on target cells (NCI-N87 Her2++, source: Cell Bank of Type Culture Collection Committee of Chinese Academy of Sciences), calculate EC50, and evaluate the in vitro activity of anti-Her2 bispecific antibodies.
[0294] The specific experimental process is as follows:
[0295] NCI-N87 cells were cultured in 1640 experimental medium containing 2% FBS (fetal bovine serum) and the cell density was adjusted to 3 × 10 5 cells / ml, 50 μl per well was inoculated in a 96-well cell culture plate (eppendorf, catalog number: 0030730199). Anti-Her2 bispecific antibodies or control drugs of different concentrations (8.1 nM, 2.7 nM, 0.9 nM, 0.3 nM, 0.1 nM, 0.03 nM, 0.01 nM, 0.003 nM, 0.001 nM, 0.0004 nM) were prepared using 1640 experimental medium, and different concentrations of antibodies or control drugs were added to the above 96-well cell culture plate, 50 μl per well. Human PBMCs were adjusted to a cell density of 1.5×10 using 1640 experimental medium. 6 cells / ml, 100μl per well. Set up the drug administration group (target cell + effector cell + antibody), target cell group (NCI-N87 cells), effector cell group (human PBMC), target cell + effector cell group, blank control group (culture medium) and lysate control group, target cell maximum release group (target cell + lysate), the effector-target ratio is 10:1. 45 minutes before the test, add 20μl / well lysate (Promega, catalog number G182A) to the target cell maximum release group and lysate control group. Use after 45 minutes. The cell lysis rate (killing rate) was detected by using a non-radioactive cytotoxicity assay kit (cytotox 96 nonradioactive cytotoxicity assay, Promega, G1780). Trastuzumab and T-DM1 (trastuzumab-emtansine conjugate, trade name Trastuzumab + pertuzumab combination (1:1), Expi HER2-1 as control drug.
[0296] Lysis rate (%) = (OD 给药组 -OD 靶细胞+效应细胞组 ) / (OD 靶细胞最大释放组 -OD 靶细胞组 )×100%
[0297] Figure 4The killing rate of NCI-N87 tumor cells by the combination of trastuzumab + pertuzumab, trastuzumab, T-DM1 and anti-Her2 bispecific antibody was shown. The ADCC-enhanced anti-Her2 bispecific antibody 23C2 HER2-2 was superior to the combination of trastuzumab + pertuzumab, trastuzumab, T-DM1 and ExpiHER2-1 in killing NCI-N87 tumor cells; among them, the EC50 of ADCC-enhanced anti-Her2 bispecific antibody 23C2 HER2-2 was 0.02447nM, the EC50 of the combination of trastuzumab + pertuzumab was 0.08267nM, the EC50 of Expi HER2-1 was 0.1048nM, the EC50 of T-DM1 was 0.07392nM, and the EC50 of trastuzumab was 0.07468nM.
[0298] Example 10 Killing of trastuzumab-resistant JIMT-1 cells by anti-Her2 bispecific antibody
[0299] NK cells were provided by human PBMC (peripheral blood mononuclear cells; effector cells) to study the killing effect of anti-Her2 bispecific antibodies on target cells (JIMT-1, source: AddexBio, Catalog #: C0006005), calculate EC50, and evaluate the in vitro activity of anti-Her2 bispecific antibodies.
[0300] The specific experimental process is as follows:
[0301] The cell density of JIMT-1 cells was adjusted to 3×10 using 1640 experimental medium containing 2% FBS (fetal bovine serum). 5 cells / ml, 50 μl per well was inoculated in a 96-well cell culture plate (eppendorf, catalog number: 0030730199). Anti-Her2 bispecific antibodies or control drugs of different concentrations (8.1 nM, 2.7 nM, 0.9 nM, 0.3 nM, 0.1 nM, 0.03 nM, 0.01 nM, 0.003 nM, 0.001 nM, 0.0004 nM) were prepared using 1640 experimental medium, and different concentrations of antibodies or control drugs were added to the above 96-well cell culture plate, 50 μl per well. Human PBMCs were adjusted to a cell density of 1.5×10 using 1640 experimental medium. 6cells / ml, 100μl per well. Set up the drug administration group (target cell + effector cell + antibody or control drug), target cell group (BT474 cells), effector cell group (human PBMC), target cell + effector cell group, blank control group (culture medium) and lysate control group, target cell maximum release group (target cell + lysate), the effector-target ratio is 20:1. 45 minutes before the test, add 20μl / well lysate (Promega, catalog number G182A) to the target cell maximum release group and lysate control group. Use after 45 minutes. The cell lysis rate (killing rate) was detected by non-radioactive cytotoxicity assay kit (cytotox 96 nonradioactive cytotoxicity assay, Promega, G1780). Trastuzumab, T-DM1, trastuzumab + pertuzumab combination (1:1), and Expi HER2-1 were used as control drugs.
[0302] Lysis rate (%) = (OD 给药组 -OD 靶细胞+效应细胞组 ) / (OD 靶细胞最大释放组 -OD 靶细胞组 )×100%
[0303] Figure 5 The killing rate of JIMT-1 tumor cells by the combination of trastuzumab + pertuzumab, trastuzumab, T-DM1 and anti-Her2 bispecific antibody is shown. ADCC-enhanced anti-Her2 bispecific antibody 23C2 HER2-2 was superior to trastuzumab + pertuzumab combination, trastuzumab, T-DM1, and Expi HER2-1 in killing JIMT-1 tumor cells; among them, the EC50 of ADCC-enhanced anti-Her2 bispecific antibody 23C2 HER2-2 was 0.01006nM, the EC50 of trastuzumab + pertuzumab combination was 0.06727nM, the EC50 of Expi HER2-1 was 0.08066nM, the EC50 of T-DM1 was 0.08357nM, and the EC50 of trastuzumab was 0.07443nM. In addition, the anti-Her2 bispecific antibody 23C2 HER2-2 had a higher cell lysis rate.
[0304] Example 11 Inhibition of proliferation of BT474 Her2+++ tumor cells by anti-Her2 bispecific antibody
[0305] 23C2 Her2-2, trastuzumab, and pertuzumab were diluted to a final concentration of 3.2 μg / ml using DMEM / F12 medium (GIBCO, catalog number 11330-032) containing 2% FBS (fetal bovine serum, manufacturer GIBCO, catalog number: 10099-141), and then diluted to 9 concentrations (1.6 μg / ml, 0.8 μg / ml, 0.4 μg / ml, 0.2 μg / ml, 0.1 μg / ml, 0.05 μg / ml, 0.025 μg / ml, 0.0125 μg / ml, 0.00625 μg / ml) in a 1:1 ratio. BT474 Her2+++ cells in the logarithmic growth phase were taken and the density was adjusted to 1×10 5 cells / ml for plating, add 100μl to each well, and set up a blank well without cells as a control. Add the above gradient diluted antibodies, 50μl per well. Culture in a carbon dioxide incubator at 37°C and 5% CO2 for 5 days. Discard the culture medium, add CCK-8 (Japan Tongren Chemical, product number: CK04) working solution, 100μl per well, incubate for 4 to 5 hours and then place in an ELISA reader (manufacturer Thermo, model: VarioskanFlash), use 630nm as the reference wavelength, read and record the absorbance value of the well plate at a wavelength of 450nm. Calculate the tumor cell proliferation inhibition rate.
[0306] Results Figure 6 The ADCC-enhanced anti-Her2 bispecific antibody 23C2 Her2-2 had a proliferation inhibition rate of 78.38% on BT474 tumor cells, which was superior to the proliferation inhibition rate of 54.12% of trastuzumab or the proliferation inhibition rate of 53.7% of trastuzumab + pertuzumab combination.
[0307] Example 12 Inhibitory effect of anti-Her2 bispecific antibody on NCI-N87 Her2++ gastric cancer xenografts in nude mice
[0308] The in vivo efficacy of anti-Her2 bispecific antibodies was evaluated in a mouse xenograft model using NCI-N87 Her2++ gastric cancer cells (cell bank of the Chinese Academy of Sciences). NCI-N87 Her2++ gastric cancer cells were prepared at a concentration of 5×10 7 pcs / ml*0.1ml / mouse, inoculated into the right armpit of nude mice (from Changzhou Cavens Experimental Animal Co., Ltd., nude mice, 14-17g, male, raised in SPF grade) under sterile conditions. The diameter of the transplanted tumor of nude mice was measured with a vernier caliper. When the tumor grew to 100-250mm 3 The animals were then divided into 5 groups:
[0309] Group 1: Control
[0310] Group 2: Expi Her2-1, 10 mg / kg
[0311] Group 3: 23C2 Her2-2, 5 mg / kg
[0312] Group 4: 23C2 Her2-2, 10 mg / kg
[0313] Group 5: Per+Tra (trastuzumab + pertuzumab), 5+5 mg / kg
[0314] Each dosing group was intravenously administered at the corresponding dose, twice a week, for about 3 weeks (6 times). Except for Group 5, the two drugs were administered in a volume of 5 ml / kg mouse body weight, and the other groups were administered in a volume of 10 ml / kg mouse body weight. Group 1 was administered 10 ml / kg PBS (Hyclone; Catalog No.: sh30256.01) by iv. When the combination group was administered, trastuzumab was administered at least 30 minutes after pertuzumab.
[0315] The anti-tumor effect of the test substance was dynamically observed by measuring the tumor diameter. The tumor volume was measured 2-3 times a week (see Table 8 for specific measurement time). The mice were weighed and the data were recorded. The general performance of the mice was observed daily.
[0316] Detection indicators:
[0317] Tumor volume (TV), calculated as: TV = 1 / 2 × a × b 2 , where a and b represent length and width respectively.
[0318] In this experiment, the drug was administered from day 0, and a total of 6 times (days 0, d3, d7, d10, d14, and d17) were administered. No animal died until day 21 of the experiment. The average weight of mice in each group showed an increasing trend ( Figure 8 ). The drug had no obvious toxic effects.
[0319] The effects of group 2 (10 mg / kg), group 3 (5 mg / kg), group 4 (10 mg / kg), and group 5 (5+5 mg / kg) on the volume of NCI-N87 gastric cancer xenografts in nude mice are shown in Table 7 and Figure 7 , 23C2 Her2-2 at a dose of 10 mg / kg was superior to Expi Her2-1 (10 mg / kg) and Per+Tra combination group (5+5 mg / kg) in inhibiting NCI-N87 gastric cancer xenograft tumors in nude mice.
[0320] Table 8: Effect of anti-HER2 bispecific antibodies on the volume of NCI-N87 gastric cancer xenograft tumors in nude mice (mean ± SD)
[0321]
[0322] Note: The drug was administered 6 times on d0, d3, d7, d10, d14 and d17.
Claims
1. A method for treating a subject having a HER2-expressing tumor, comprising administering to the subject a therapeutically effective amount of an antigen-binding construct, wherein: The antigen-binding construct comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, preferably, the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, preferably, the mutated amino acid is Y.
2. The method of claim 1, wherein the heavy chain variable region of the first antigen-binding fragment comprises a K30E mutation according to the Kabat numbering system, or / and the light chain variable region of the first antigen-binding fragment comprises a F53Y mutation according to the Kabat numbering system.
3. The method of claim 1 or 2, wherein the first antigen-binding fragment comprises a group of CDRs selected from the following: i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively; ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively; iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively; iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively; v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively; vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NOs: 30, 34 and 32, respectively; vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively; viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively; or ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
4. The method according to any one of claims 1 to 3, comprising contacting tumor cells with the antigen-binding construct, thereby killing HER2-expressing tumor cells or inhibiting the growth of HER2-expressing tumor cells.
5. The method according to any one of claims 1 to 4, wherein the tumor is biliary tract cancer, carcinosarcoma, esophageal cancer, gastroesophageal junction cancer, breast cancer, gastric cancer, pancreatic cancer, head and neck cancer, colorectal cancer, kidney cancer, cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, malignant melanoma, pharyngeal cancer, oral cancer or skin cancer.
6. The method according to any one of claims 1-5, comprising administering an effective amount of the antigen-binding construct or the pharmaceutical composition to a cell, thereby inhibiting, reducing or blocking HER2 signaling in the cell.
7. A method for enhancing the aggregation resistance of an antigen-binding construct, wherein: The antigen-binding construct comprises a first antigen-binding fragment that monovalently and specifically binds to the ECD4 antigen of HER2 on HER2-expressing cells, wherein the first antigen-binding fragment is a scFv; the method comprises: modifying the antigen-binding construct so that the heavy chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 30 according to the Kabat numbering system, and the mutated amino acid is E, or / and the light chain variable region of the first antigen-binding fragment comprises an amino acid mutation at position 53 according to the Kabat numbering system, and the mutated amino acid is Y.
8. The method for enhancing the aggregation resistance of an antigen-binding construct according to claim 7, wherein the antigen-binding construct further comprises a second antigen-binding fragment that monovalently and specifically binds to the ECD2 antigen of HER2 on HER2-expressing cells; the second antigen-binding fragment is Fab.
9. The method of enhancing the aggregation resistance of an antigen-binding construct according to claim 7 or 8, wherein the first antigen-binding fragment comprises a group of CDRs selected from the following: i. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NO: 27, 28, 29, respectively; ii. comprising a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 27, 28, 29, respectively; iii. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NO: 30, 34, 32, respectively; iv. comprising a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence having at least 80% identity with the amino acid sequence according to SEQ ID NO: 30, 34, 32, respectively; v. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 27, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 34 and 32, respectively; vi. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 27, 28, 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise an amino acid sequence that is at least 80% identical to the amino acid sequence according to SEQ ID NO: 30, 34, 32, respectively; vii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively; viii. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise amino acid sequences according to SEQ ID NOs: 30, 33 and 32, respectively; ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively; or ix. comprising a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, wherein the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 44, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprise the amino acid sequences according to SEQ ID NOs: 30, 31 and 32, respectively.
10. The method for enhancing the aggregation resistance of an antigen-binding construct according to claim 7 or 8, wherein the first antigen-binding fragment is a scFv and comprises a heavy chain variable region of trastuzumab or a mutant thereof and a light chain variable region of trastuzumab or a mutant thereof, wherein the mutant of the heavy chain variable region comprises a K30E mutation, and the mutant of the light chain variable region comprises a F53Y mutation.
